Ipamorelin: Research Overview of a Selective Growth Hormone Secretagogue

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. It was developed by Novo Nordisk in the late 1990s as part of a broader programme to identify selective growth hormone (GH) releasing compounds with improved pharmacological profiles compared to earlier secretagogues such as GHRP-2 and GHRP-6.

With a molecular weight of approximately 711.9 Da and a CAS number of 170851-70-4, Ipamorelin is water-soluble and typically supplied as a lyophilised white powder. Its relatively small size and high selectivity have made it a widely studied tool compound in preclinical metabolic and endocrinological research.

For research use only. Not intended for human or veterinary use.

---

Mechanism of Action: The Ghrelin Receptor Pathway

Ipamorelin exerts its effects primarily by acting as an agonist at the growth hormone secretagogue receptor type 1a (GHSR-1a), commonly referred to as the ghrelin receptor. This receptor is a G protein-coupled receptor (GPCR) expressed predominantly in the pituitary gland and hypothalamus, where it plays a central role in regulating GH release.

Upon binding to GHSR-1a, Ipamorelin activates a Gαq/11-mediated signalling cascade that leads to phospholipase C activation, inositol triphosphate (IP₃) generation, and intracellular calcium mobilisation. This calcium signal triggers the fusion of GH-containing secretory granules with the plasma membrane of somatotroph cells, resulting in pulsatile GH release into the bloodstream.

What distinguishes Ipamorelin from earlier GHRPs is its high receptor selectivity. Research published in the Journal of Endocrinology (Raun et al., 1998) demonstrated that Ipamorelin stimulates GH release with potency comparable to GHRP-6 but without the significant co-stimulation of adrenocorticotropic hormone (ACTH), cortisol, or prolactin observed with first-generation secretagogues. This selectivity profile has made Ipamorelin a preferred tool compound for studying isolated GH axis effects in preclinical models.

---

Growth Hormone Release: Preclinical Findings

Pulsatile GH Secretion

The original characterisation of Ipamorelin by Raun and colleagues (1998) established its capacity to induce robust, dose-dependent GH release in rats. The compound produced GH pulses that closely mimicked the physiological pattern of endogenous GH secretion — a property considered important for maintaining normal downstream IGF-1 signalling without disrupting the pulsatile rhythm that governs many GH-dependent processes.

Subsequent studies confirmed that Ipamorelin acts synergistically with growth hormone-releasing hormone (GHRH). When co-administered in rodent models, the combination produced GH responses significantly greater than either compound alone, consistent with their complementary mechanisms: GHRH stimulates GH synthesis and release via cAMP-dependent pathways, while Ipamorelin amplifies release through the calcium/IP₃ pathway and simultaneously suppresses somatostatin tone.

IGF-1 Axis Activation

GH released in response to Ipamorelin stimulates hepatic production of insulin-like growth factor 1 (IGF-1), the primary mediator of many GH-dependent anabolic and metabolic effects. Research in rodent models has consistently demonstrated that repeated Ipamorelin administration raises circulating IGF-1 levels, with the magnitude of the increase correlating with dose and frequency of administration.

A study by Svensson and colleagues (2000) in Growth Hormone & IGF Research examined the effects of continuous subcutaneous Ipamorelin infusion in rats over 15 days. Animals receiving Ipamorelin showed significant increases in body weight, tibial growth plate width, and serum IGF-1 compared to controls, with effects comparable to those produced by direct GH administration. Importantly, no changes in cortisol, ACTH, or thyroid hormone levels were observed, reinforcing the compound's selectivity.

---

Bone and Connective Tissue Research

One of the most extensively studied areas of Ipamorelin research concerns its effects on bone metabolism. The GH/IGF-1 axis plays a critical role in bone formation, remodelling, and mineral density, making GH secretagogues of interest in models of age-related bone loss and fracture healing.

Johansen and colleagues (1999) published a landmark study in Growth Hormone & IGF Research examining the effects of Ipamorelin on bone formation in ovariectomised rats — a standard preclinical model of oestrogen-deficiency-related bone loss. Animals treated with Ipamorelin showed significant increases in bone mineral density (BMD) at the lumbar spine and femur compared to vehicle-treated controls. Histomorphometric analysis revealed increased osteoblast activity and bone formation rate, consistent with IGF-1-mediated stimulation of osteoblast differentiation and collagen synthesis.

A follow-up study by the same group investigated the effects of Ipamorelin on cortical bone geometry and strength in aged rats. Ipamorelin-treated animals demonstrated improved cortical thickness and estimated bone strength compared to age-matched controls, suggesting potential utility as a tool compound in models of age-related skeletal deterioration.

---

Gastrointestinal Motility Research

A distinct and clinically relevant area of Ipamorelin research concerns its effects on gastrointestinal (GI) motility. GHSR-1a receptors are expressed throughout the enteric nervous system, and ghrelin itself is known to stimulate gastric emptying and intestinal motility. Ipamorelin, as a GHSR-1a agonist, has been investigated as a tool compound in preclinical models of post-operative ileus and GI dysmotility.

Research by Greenwood-Van Meerveld and colleagues demonstrated that Ipamorelin accelerated gastric emptying and colonic transit in rodent models. These effects were mediated through enteric GHSR-1a receptors rather than through GH-dependent mechanisms, highlighting the compound's utility in studying the peripheral ghrelin receptor system independently of its central endocrine effects.

This GI research formed the basis for Helsinn Therapeutics' clinical development programme for Ipamorelin in combination with the 5-HT₄ receptor agonist cisapride (the compound RQ-00000005), though this programme was ultimately discontinued. The preclinical data nonetheless established Ipamorelin as a valuable tool for studying enteric nervous system pharmacology.

---

Selectivity Profile: Comparison with Other GHRPs

A key feature of Ipamorelin's research utility is its selectivity relative to earlier growth hormone releasing peptides. The following table summarises the comparative receptor selectivity profiles of the major GHRPs based on published preclinical data:

Data derived from Raun et al. (1998), Arvat et al. (2001), and Ghigo et al. (1997).

This selectivity profile makes Ipamorelin particularly valuable in research designs where isolated GH axis effects are required without the confounding influence of HPA axis activation or elevated prolactin levels.

---

Pharmacokinetics in Preclinical Models

Ipamorelin has a short plasma half-life of approximately 2 hours in rodent models following subcutaneous administration, consistent with its pentapeptide structure and susceptibility to proteolytic degradation. Peak plasma GH levels are typically observed within 15–30 minutes of administration, with GH returning to baseline within 3–4 hours.

The compound's short half-life necessitates repeated or continuous administration in chronic preclinical studies, which has been achieved through subcutaneous injection protocols, osmotic mini-pump infusion, and more recently through depot formulation strategies. The pulsatile GH release pattern produced by intermittent Ipamorelin administration more closely approximates physiological GH secretion than continuous infusion, which is associated with GH receptor downregulation in some models.

---

Safety and Tolerability in Preclinical Studies

Across the published preclinical literature, Ipamorelin has demonstrated a favourable safety profile at doses used in research settings. Chronic administration studies in rats and dogs have not identified significant adverse effects on cardiovascular parameters, liver function, or haematological indices at doses producing robust GH responses.

The absence of significant ACTH/cortisol stimulation is particularly relevant from a safety perspective, as chronic HPA axis activation is associated with immunosuppression, metabolic dysregulation, and bone loss in animal models — effects that would confound interpretation of GH-related outcomes. Ipamorelin's selectivity therefore simplifies experimental design and reduces the risk of off-target effects in long-term studies.

---

Research Applications and Experimental Considerations

Ipamorelin is used as a tool compound in a range of preclinical research contexts, including:

• GH axis pharmacology: Characterising GHSR-1a receptor function, GH pulse dynamics, and downstream IGF-1 signalling
• Metabolic research: Investigating GH-dependent effects on body composition, lipid metabolism, and insulin sensitivity in rodent models
• Skeletal biology: Studying GH/IGF-1-mediated bone formation, remodelling, and fracture healing
• Ageing models: Examining the effects of GH axis supplementation on age-related changes in muscle mass, bone density, and metabolic function
• Enteric nervous system research: Probing peripheral GHSR-1a function in GI motility models

Researchers working with Ipamorelin should note that its effects are dependent on intact pituitary function; the compound stimulates GH release rather than replacing it, and its efficacy is therefore reduced in models with compromised somatotroph populations. Reconstitution in bacteriostatic water and storage at -20°C are standard protocols for maintaining compound stability.

---

Key Research References

• Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552–561.
• Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology & Metabolism. 1998;83(2):362–369.
• Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106–113.
• Greenwood-Van Meerveld B, Kriegsman M, Nelson R. Ghrelin as a target for gastrointestinal motility disorders. Peptides. 2011;32(11):2352–2356.
• Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. Journal of Clinical Endocrinology & Metabolism. 2001;86(3):1169–1174.

---

All information presented in this article is for educational and research purposes only. Ipamorelin is a research compound and is not approved for human or veterinary use. Peptidex supplies research-grade compounds exclusively for in-vitro and preclinical laboratory research.